鼠李糖乳杆菌GG与安慰剂治疗儿童急性胃肠炎的比较
该研究为前瞻性、随机、双盲试验,纳入美国10个儿科急诊科的3月龄至4岁急性胃肠炎患儿,比较5天鼠李糖乳杆菌GG(1×10^10 CFU,每日两次)与安慰剂。主要终点为入组后14天内改良Vesikari量表评分≥9分的中重度胃肠炎,鼠李糖乳杆菌GG组55/468例(11.8%) vs 安慰剂组60/475例(12.6%)(RR 0.96,95%CI 0.68-1.35,P=0.83),无显著差异。腹泻持续时间、呕吐持续时间、日托缺勤及家庭传播率两组亦无显著差异。在学龄前急性胃肠炎患儿中,鼠李糖乳杆菌GG未显示优于安慰剂的结局。
要点
- 3月龄至4岁急性胃肠炎患儿,5天鼠李糖乳杆菌GG(1×10^10 CFU每日两次)与安慰剂相比,14天内改良Vesikari评分≥9分的比例无显著差异(11.8% vs 12.6%,RR 0.96,95%CI 0.68-1.35,P=0.83)。
- 腹泻持续时间中位数两组无显著差异(鼠李糖乳杆菌GG组49.7小时 vs 安慰剂组50.9小时,P=0.26)。
- 呕吐持续时间中位数两组均为0小时(P=0.17),日托缺勤中位数两组均为2天(P=0.67),均无显著差异。
- 家庭传播率两组无显著差异(鼠李糖乳杆菌GG组10.6% vs 安慰剂组14.1%,P=0.16)。
- 该研究为美国10个儿科急诊科的多中心随机双盲试验,971例参与者中943例(97.1%)完成试验。
适用人群与场景
- 3月龄至4岁急性胃肠炎患儿,就诊于美国10个儿科急诊科。
- 参与者接受5天鼠李糖乳杆菌GG 1×10^10 CFU每日两次或匹配安慰剂。
诊断标准与关键阈值
- 主要终点中重度胃肠炎定义:入组后14天内改良Vesikari量表总分≥9分(评分范围0-20分,分数越高病情越重)。
处置流程与药物剂量
- 鼠李糖乳杆菌GG 1×10^10 CFU,每日两次,疗程5天。
研究设计与关键结果
- 研究类型:前瞻性、随机、双盲试验;样本量971例,完成试验943例(97.1%);10个美国儿科急诊科;人群为3月龄至4岁急性胃肠炎患儿,中位年龄1.4岁(四分位距0.9-2.3),男性513例(52.9%)。
- 主要终点:入组后14天内改良Vesikari评分≥9分的比例,鼠李糖乳杆菌GG组55/468例(11.8%) vs 安慰剂组60/475例(12.6%),RR 0.96(95%CI 0.68-1.35),P=0.83,无显著差异。
- 次要终点:腹泻持续时间中位数鼠李糖乳杆菌GG组49.7小时 vs 安慰剂组50.9小时(P=0.26);呕吐持续时间中位数两组均为0小时(P=0.17);日托缺勤中位数两组均为2天(P=0.67);家庭传播率鼠李糖乳杆菌GG组10.6% vs 安慰剂组14.1%(P=0.16),均无显著差异。
证据类型、等级与局限
- 证据类型:前瞻性、随机、双盲试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在学龄前急性胃肠炎患儿中,接受5天鼠李糖乳杆菌GG者与接受安慰剂者相比未获得更好结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute gastroenteritis develops in millions of children in the United States every year, and treatment with probiotics is common. However, data to support the use of probiotics in this population are limited.
METHODS: We conducted a prospective, randomized, double-blind trial involving children 3 months to 4 years of age with acute gastroenteritis who presented to one of 10 U.S. pediatric emergency departments. Participants received a 5-day course of Lactobacillus rhamnosus GG at a dose of 1×1010 colony-forming units twice daily or matching placebo. Follow-up surveys were conducted daily for 5 days and again 14 days after enrollment and 1 month after enrollment. The primary outcome was moderate-to-severe gastroenteritis, which was defined as an illness episode with a total score on the modified Vesikari scale of 9 or higher (scores range from 0 to 20, with higher scores indicating more severe disease), within 14 days after enrollment. Secondary outcomes included the duration and frequency of diarrhea and vomiting, the duration of day-care absenteeism, and the rate of household transmission (defined as the development of symptoms of gastroenteritis in previously asymptomatic household contacts).
RESULTS: Among the 971 participants, 943 (97.1%) completed the trial. The median age was 1.4 years (interquartile range, 0.9 to 2.3), and 513 participants (52.9%) were male. The modified Vesikari scale score for the 14-day period after enrollment was 9 or higher in 55 of 468 participants (11.8%) in the L. rhamnosus GG group and in 60 of 475 participants (12.6%) in the placebo group (relative risk, 0.96; 95% confidence interval, 0.68 to 1.35; P=0.83). There were no significant differences between the L. rhamnosus GG group and the placebo group in the duration of diarrhea (median, 49.7 hours in the L. rhamnosus GG group and 50.9 hours in the placebo group; P=0.26), duration of vomiting (median, 0 hours in both groups; P=0.17), or day-care absenteeism (median, 2 days in both groups; P=0.67) or in the rate of household transmission (10.6% and 14.1% in the two groups, respectively; P=0.16).
CONCLUSIONS: Among preschool children with acute gastroenteritis, those who received a 5-day course of L. rhamnosus GG did not have better outcomes than those who received placebo. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; ClinicalTrials.gov number, NCT01773967 .).
参考来源
- Schnadower D, Tarr PI, Casper TC, et al. Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. N Engl J Med. 2018. PMID: 30462938. doi:10.1056/NEJMoa1802598
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。